High dose chemotherapy for poor prognosis breast cancer: Systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 33, Issue 4, 2007, Pages 325-337

  Farquhar, Cynthia M ^a   Marjoribanks, Jane ^a   Lethaby, Anne ^b   Basser, Russell ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Royal Melbourne Hospital ^*  (Chile)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Breast cancer; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AXILLARY LYMPH NODE; BLADDER DISEASE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COCHRANE LIBRARY; COLITIS; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; EMBASE; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAIR LOSS; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INCIDENCE; INFECTION; INTERNET; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; LIVER FAILURE; LIVER VENOOCCLUSIVE DISEASE; LUNG DISEASE; LUNG FIBROSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MEDLINE; MENOPAUSE; META ANALYSIS; METHODOLOGY; MORBIDITY; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 34249063695     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.01.007     Document Type: Review

References (31)

1. World Health Organisation, Globocan 2000. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. Lyon: IARC Press; 2001.
2. Bray F., et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 1 (2002) 99-166
3. Early Breast Cancer Trialists' Collaborative Group, Multi-agent chemotherapy for early breast cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software; 2002.
4. Nemoto T., et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45 (1980) 2917-2924
5. Antman K., et al. A phase II study of high dose cyclophosphamide, thiopeta and carboplatinum with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10 (1992) 102-110
6. Peters W.P., Shpall E.J., and Jones R.B. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6 (1988) 1368-1376
7. Williams S.F., Gilenski T., and Mick R. High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer: a follow-up report. J Clin Oncol 10 (1992) 1743-1747
8. Eddy D.M. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10 (1992) 657-670
9. Farquhar C., et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer (Cochrane Review). The Cochrane database of systematic reviews (2005), Wiley, Chichester, UK
10. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 22 (1959) 719-748
11. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in meta-analysis. Stat Med 21 11 (2002) 1538-1558
12. Leonard R.C.F., et al. Conventional adjuvant chemotherapy versus single-cycle autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomised trial. J Nat Canc Inst 96 (2004) 1076-1083
13. Peters W.P., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23 (2005) 1-10
14. Rodenhuis S., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 1 (2003) 7-15
15. Rodenhuis S., et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352 (1998) 515-521
16. Tallman M.S., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349 1 (2003) 17-26
17. Zander A.R., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22 (2004) 1-11
18. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Onc 24 3 (2006) 370-378
19. Coombes R.C., et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16 (2005) 726-734
20. Tokuda Y et al. Randomized Phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208) [poster presentation]. American Society of Clinical Oncology; 2001.
21. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+) [abstract]. American Society of Clinical Oncology; 2001.
22. Hortobagyi G.N., et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92 3 (2000) 225-233
23. Roche H., et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10 1 (2003) 42-47
24. Nitz U.A., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366 (2005) 1935-1944
25. Isaacs RE et al. A phase III multi-institution randomized study comparing standard adjuvant chemotherapy to intensification with high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell (PBPC) rescue in patients with stage II/IIIA breast cancer with 4-9 involved axillary lymph nodes (abstract); 1998.
26. Nabholtz JM. A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) with TAC followed by high dose chemotherapy with mitoxantrone, cyclophosphamide and vinorelbine (HDCT) with autologous peripheral stem cell transplantation and G-CSF in adjuvant treatment of operable breast cancer with 4 or more positive axillary nodes; 2002.
27. Pouillart P. Etude prospective multicentrique randomisée de phase III évaluant l'apport de l'intensification thérapeutic avec autotransplantation de cellules hématopoïétiques dans les cancers du sein non métastasés avec envahissement ganglionnaire; 2002.
28. Nieto Y., et al. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant 6 (2000) 476-495
29. Bearman SI. NCI high priority trial: Phase III randomized study of intensive sequential doxorubicin, paclitaxel and cyclophosphamide versus doxorubicin and cyclophosphamide followed by STAMP I and STAMP V combination chemotherapy with autologous stem cell rescue in women with primary breast cancer and at least 4 involved axillary lymph nodes; 2001.
30. Bergh J., et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356 (2000) 1384-1391
31. Bezwoda W. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high-risk, surgically treated, primary breast cancer (abstract); 1999.